Introduction cell contacts (49).
The first population is composed of thin circumferential actin bundles and the second is localized at cell-cell junctions. These two actin populations are regulated by distinct mechanisms. Indeed, the actin bundles are formed by reorganizating pre-existing actin filaments and the junctional filaments by de novo actin polymerization. To ensure the dynamic coordination between cadherin homophilic liganding and the remodelling of both actin populations, more regulatory proteins are required than assumed previously (33). To bring some light on the connection existing between the VE-cad-based complex and the actin cytoskeleton, we examined the composition of the junctional VE-cad-based complex extracted from confluent endothelial cell monolayers by combining anti-VE-cad immunoprecipitation (IP) with proteomic tools, thereby identifying novel VE-cad partners (unpublished data). In these experiments, annexin 2 (A2) was identified as one of the most abundant VE-cad partners.
The superfamily of annexins forms a Ca 2+ -dependent regulated class of proteins able to dock in a reversible manner onto the inner leaflet of the plasma membrane by interacting with acidic phospholipids (19). A2 interacts, via its N-terminal domain, with p11 (also called S100A10) to form a heterotetramer in which a central p11 dimer connects two A2 monomers (12, 26, 32) . Moreover, A2 exhibits an F-actin binding site localized within the last 9 amino acid residues of its C-terminus (17). A2 is not only able to bind to actin but can also bundle actin filaments (22). It participates in the regulation of membrane organization and more particularly in the assembly of cholesterol rafts (2). These A2 containing-cholesterol rafts are highly dynamic membrane domains that serve as F-actin assembly platforms. The precise role of A2 in the dynamic remodelling of these platforms remains to be elucidated. Nevertheless, Hayes et al. recently demonstrated that A2 regulates actin polymerization by interfering with the barbed ends of growing actin filaments (23).
In the present manuscript, we examined the role played by A2 in the regulation and/or stabilization of endothelial adherens junctions. We have demonstrated by immunoprecipitation that A2 interacts directly with the junctional VE-cad-based complex. In addition, our results prove that A2 is absolutely required to maintain VE-cad at cell-cell junctions. Our data also indicate that A2 docks the VE-cad-based complex to cholesterol rafts and binds actin fibers to the complex as cells reach confluence. Thus, connection of the VE-cad-based complex to both cholesterol rafts and to A2-anchored actin filaments strengthens adherens junctions in the ultimate step of maturation.
Reciprocally, it can be assumed that the opening of adherens junction may result from A2
and VE-cad-based complex decoupling. To test this hypothesis, we evaluated effects of the pro- angiogenic Vascular Endothelial Growth Factor (VEGF) on the A2/VE-cad-based complex organization in HUVECs. We showed that VEGF induced a drastic perturbation of the VE-cad localization, a release of A2 from the plasma membrane to the cytoplasm and a decoupling of A2 from the VE-cad-based complex. This dissociation leads to the disconnection of the VE-cad complex from the actin cytoskeleton, an event that may constitute one of the earliest steps in adherens junction destabilization favoring the increase of vascular permeability. 
Materials and methods

Reagents and antibodies
The monoclonal anti-VE-cad antibody BV9 was from Santa Cruz Biotechnologies. The polyclonal antibody directed against human VE-cad anti-Cad3 was produced as previously described (24). Anti-annexin 2, anti-annexin 1, anti-annexin 5, anti-α-, β-, γ-catenins and anti-PECAM-1 antibody were purchased from BD Biosciences. Anti-N-cadherin antibody and rabbit non-immune IgG were purchased from DakoCytomation. Anti-β-actin, FITC-and TRITCphalloidin, methyl β cyclodextrin (MβCD) and latrunculin B (La B) were from Sigma-Aldrich.
Cy2-or Cy3-goat anti-rabbit antibodies and Cy2-or Cy3-goat anti-mouse antibodies were purchased from Immunotech. Cy5-goat anti-mouse and Cy5-goat anti-rabbit antibodies were provided by Amersham Biosciences. Alexa 488-labelled goat-anti-IgG1, Cy3-labelled goat-antiIgM were purchased from Molecular Probes. Recombinant VEGF was from PeproTech Inc.
Cell culture
HUVECs were isolated and cultured as previously described (30). Only cells on passage 2 were used.
Immunofluorescence microscopy
After treatment, cells cultured on fibronectin-coated glass coverslips were fixed and permeabilized in methanol 85%, 15 mM PIPES pH 7.7, 2 mM MgCl 2 for 10 min at -20°C and blocked with 0.5% BSA in PBS. After several washing steps in PBS, cells were incubated with primary antibodies and then with the adequate secondary antibodies. The coverslips were mounted onto slides with DAPI-containing mowiol 40-88 (Sigma-Aldrich). Cells were then observed using an Axioplan 2 microscope (Zeiss) equipped with an Achroplan x 50 objective.
Images were captured with an AxioCam MR camera using Axiovision software.
When specified, cells were observed on a confocal microscope TCS-SP2 (Leica) with a x63/1.4 objective. For image acquisition (1024x1024, 8bit), Alexa 488, TRITC, Cy5 and DAPI fluorescence were excited and collected sequentially (400 Hz line by line) by using the 488nm wavelength of an argon laser for Alexa 488, the 543nm wavelength of an helium-neon laser for TRITC, the 633nm wavelength of an helium-neon laser for Cy5 excitation and the 405nm wavelength of a photodiode for DAPI. Fluorescence emission was collected from 498 to 540nm for Alexa488, from 573 to 630 nm for TRITC, from 644 to 720nm for Cy5 and from 410 to 460nm for DAPI. 
Immunoprecipitation (IP)
Affinity beads were prepared as followed: 60 µg of affinity-purified anti-Cad 3 or 6 µg of anti-A2 antibodies were mixed with 30 µL of a suspension of protein A-or protein G-Sepharose beads respectively (Sigma-Aldrich). After a 2 hour incubation time at 4°C, centrifugation at 200 g during 5 min and several washs in PBS, grafted beads were equilibrated in the lysis buffer L (10 mM PIPES pH 7, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EDTA, 2 mM PMSF, 5 µg/mL leupeptine, 2 µg/mL aprotinine) containing 0.5% IGEPAL CA-630. HUVEC monolayers were washed twice with PBS, lysed in 1 mL of 0.5% IGEPAL-containing buffer L for 20 min at 4°C. After lysate centrifugation at 15 000 g for 10 min, supernatants were incubated overnight at 4°C under continuous mixing with antibody-grafted protein A-/G-Sepharose beads.
IPs were each time performed on a 78 cm² cell monolayer. To elute immunoprecipitated proteins, beads were washed 3 times in lysis buffer and then boiled in 50 µL Laemmli buffer for 10 min.
Whole elutions were loaded on SDS-PAGE for Western blot analysis.
Cell treatments
After brief washing in PBS, HUVEC monolayers were incubated in culture medium containing either 3.8 mM MβCD for 30 min or 0.5 µM La B for 5 min. To determine whether VE-cad was internalized following La B treatment, La B-treated cells were incubated with trypsin-EDTA at 0.5 g/L for 2 min prior cell lysis and Western blot analysis.
HUVECs were starved between 3 and 6h before a 30 min stimulation with either VEGF (50 ng/mL) in serum-free medium.
Subcellular fractionations
To separate cytoplasm from membrane, HUVEC monolayers were lysed in detergent-free buffer L. After centrifugation at 1000 g for 3 min at 4°C to remove unbroken cells, supernatants were collected and recentrifuged at 150 000 g for 30 min at 4°C. The resulting supernatants corresponded to the non-membrane fractions, designated as the cytoplasmic fraction afterwards in the manuscript, and pellets, resuspended in 0.5% IGEPAL-containing buffer L, to the membrane fractions. To isolate cholesterol raft-associated proteins, membrane pellets were resuspended in buffer L containing 0.01% digitonin. After a 20 min incubation on ice, homogenates were centrifuged at 150 000 g for 30 min at 4°C. The resulting supernatants 
LC-MS/MS
Cholesterol raft-associated proteins were separated on 4-12% gradient gel (Criterion TM XT Precast, BioRad) and gels were stained by Coomassie blue (Bio-Safe Coomassie G250 stain, BioRad). The Coomassie-blue stained protein bands were in-gel digested with trypsin and the recovered peptides were separated by liquid chromatography on silica C18 column (Dionex)
prior to analysis on an integrated nanoLC-MS/MS system. Peptide identification from the resulting MS/MS dataset was achieved using an in-house MASCOT server (Matrix Sciences, London).
Western blotting
Cell extracts were analyzed under reducing conditions by SDS-PAGE using either 10% TrisGlycine or 15% Tris-Tricine home-made gels, or 4-12% gradient Criterion TM XT gels and electro-transferred onto a pure nitrocellulose membrane (BioRad). After blocking with 5% nonfat dry milk, proteins were detected by specific primary antibodies and horseradish peroxidaseconjugated goat anti-mouse or anti-rabbit antibodies (Sigma-Aldrich). The immunoreactive bands were revealed using the ECL Western blotting detection kit (Amersham Biosciences).
Signals recorded on autoradiography films (Amersham Biosciences) were quantified using a Gel Doc EQ apparatus and Quantity One software (BioRad). First, the subcellular localization of A2 was explored in density-increasing HUVEC monolayers. To do so, the membrane and cytoplasmic fractions were separated from subconfluent and confluent HUVECs by ultracentrifugation and analyzed by Western blot ( Fig   1A) . As expected, in subconfluent as well as in confluent cells, VE-cad was found in the membrane fraction (Fig 1A, lanes 2 and 4) . The absence of VE-cad in the cytoplasm attested that this fraction was not contaminated by membranes (Fig 1A, lanes 1 and 3) . On the contrary, it was observed that A2, which was exclusively found in the cytoplasmic fraction in subconfluent cells, distributed between the cytoplasm and the membranes in confluent cells (Fig 1A) . These results
siRNA interference
showed that A2 partially translocated from cytoplasm to membranes as cell confluence increased.
To demonstrate A2 translocation, an immunocytochemical localization of A2 was performed on HUVECs plated at different densities. Fig 1B shows that A2 is exclusively cytoplasmic in subconfluent cells (Subconfluent, A2, and Magn., magnified image) and accumulates at the plasma membrane as cell confluence increases (Confluent, A2, and Magn., magnified image). To assess whether VE-cad and A2 co-localize at cell-cell contacts, confocal microscopy analysis was performed on 650nm optical sections (Fig 1C, larger areas are also shown in supplementary data Fig S1) . This revealed that VE-cad and A2 effectively co-localized along the whole cell-cell junction (Fig 1C, white) . Nevertheless, some minor restricted areas exhibit juxtaposed red and green dots, indicating thus that a few amount of A2, even thought localized at the plasma membrane, was not associated with the VE-cad-based junction (Fig 1C,   merge) . Moreover, at cell-cell contacts, A2 and VE-cad co-localize with the actin cytoskeleton (Fig 1B, Confluent, A2 , and Magn., magnified image).
It is notable that the adherens junction architecture changes with increasing cell density. constitute the actin cortical ring in confluent cells (Fig 1B, actin) . This indicates that, as cell confluence is established, the actin cytoskeleton undergoes a major remodelling which correlates with the arrival of A2 at cell-cell junctions.
Connection of annexin 2 to the VE-cadherin-based complex
To assess whether A2 is associated with the VE-cad/catenin complex, A2
immunoprecipitates were analyzed by Western blot. As reported in Fig 2 A , antibodies directed against VE-cad, p120, α-, β-and γ-catenins recognized bands of 150, 120-100, 110, 93 and 83-80 kDa respectively. Besides VE-cad and catenins, p11, the protein known to form a heterotetrameric complex with A2 at the plasma membrane (39), was also detected in the anti-A2
immunoprecipitates (Fig 2 A) . Conversely, anti-VE-cad immunoprecipitation showed association with A2 only when cells have reached confluence (Fig 2 B) . Other annexins expressed in endothelial cells such as annexin 1 (A1) and annexin 5 (A5) ( Table 1) , were not detected in anti-VE-cad IPs (Fig 3 A) . Moreover, VE-cad was detected neither in anti-A1 (Fig 3 B) nor anti-A5 (Fig 3 C) IPs performed on confluent HUVECs. Altogether, these data indicate that the A2/p11 complex is associated with the VE-cad/catenin complex at adherens junction sites in confluent cells. It is noteworthy that N-cadherin, the other cadherin expressed by endothelial cells, and PECAM1, a transmembrane receptor that localizes at interendothelial cell-cell contacts, were not detected in anti-A2 IPs (Fig 2A) . Altogether, the results attested that A2 interacts specifically with the VE-cadherin-based complex.
Based on these results, A2 and the VE-cad-based complex may be either directly connected or associated via actin filaments. To resolve this question, the actin cytoskeleton was depolymerized in confluent HUVECs with La B (11). Once the membrane and cytoplasm fractions were separated from cells either treated or not with La B, the subcellular localization of A2, actin and VE-cad was analyzed by Western blot (Fig 4 A) . Quantification of the blotted bands indicated that the amount of membrane-associated A2 remained approximately constant before and after La B treatment (Fig 4 A) . By contrast, a loss of 40% of the amount of membrane-associated actin was observed after La B treatment (Fig 4 A) . This indicated that actin depolymerization did not induce a release of A2 from membranes. This is in agreement with confocal and phase contrast microscopy analyses performed on untreated and La B-treated HUVECs (Fig 4 B) . The drug-induced depolymerisation of actin filaments lead to cell retraction and cell-cell junction disruption (Fig 4 B, PC) . In spite of this drastic treatment, A2 remained colocalized with VE-cad at the cell edge, suggesting that VE-cad and A2 interact without requiring HUVECs treated or not with La B (Fig 4 C) and the blotted bands were quantified (data not shown). Similar amounts of A2 were detected in VE-cad immunoprecipitates isolated from either La B-or non-treated cells. Conversely, in A2 immunoprecipitates, the amount of VE-cad coimmunoprecipitated remained unchanged between treated and untreated cells (Fig 4 C) . These experiments revealed that, after actin cytoskeleton depolymerization, A2 did not decouple from the VE-cad-based complex. It could be concluded that, in confluent endothelial cells, the association of the A2/p11 complex to the junctional VE-cad-based complex does not require actin filaments.
Contribution of cholesterol raft-associated annexin 2 to the stability of adherens junctions
To evaluate the contribution of A2 in the localization of VE-cad at cell-cell junctions, A2
was knocked-down in HUVECs using a pool of two selected small interfering RNA (siRNA).
Practically, one day after the second siRNA transfection, HUVECs were plated on glass coverslips and allowed to grow for additional 24 or 48 h periods of time prior to fixation. Four days after A2 siRNA transfection, immunoblot analysis indicated that 50 to 70% of A2 expression was abrogated while a scrambled siRNA had no effect (Fig 5 A) . The effect observed with the A2 siRNA was specific since the expression of proteins such as actin, VE-cad and annexins 1 and 5 was not down-regulated following A2 siRNA transfection (Fig 5 A) .
siRNA transfection induced no cell retraction as attested by phase contrast microscopy (data not shown). The effect of A2 down-regulation on VE-cad localization was then analyzed by immunofluorescence microscopy 24 and 48h after cell seeding on glass coverslips. At 24 or 48 h post seeding time, the immunofluorescence signal for A2 was undetectable in some cells while unaffected in others. This heterogeneity reflected the difficulty to transfect siRNA in HUVECs.
As expected, transfection of the scrambled siRNA had no effect on A2 and VE-cad localization.
At 24 h post-cell seeding time, A2 siRNA induced a drastic loss of VE-cad at adherens junctions between adjacent transfected cells (Fig 5 B) . At 48 h post-cell seeding time, VE-cad began to reappear at cell-cell junctions exhibiting a zigzag staining pattern, a characteristic feature of immature junctions. Thus, it could be concluded that A2 down-regulation significantly disturbs the localization of VE-cad at cell-cell junctions.
Knock-down by siRNA affected the whole pool of cellular A2. Consequently, it was difficult to state whether either membrane-associated A2 or cytoplasmic A2 was involved in the observed phenotype. To discriminate between these two possibilities, the cholesterol raftdisrupting drug MβCD (10) was used to release A2 from the plasma membrane. Subcellular 60% of the membrane-bound A2 was released to the cytoplasm whereas, as expected, in confluent untreated HUVECs, A2 was mainly associated to membranes (Fig 6 A and B) . 82% of actin remained associated with membranes after MβCD treatment indicating that actin was weakly affected by the drug (Fig 6 A and B) .
As revealed by immunofluorescence microscopy, treatment of confluent HUVECs with
MβCD provoked a disruption of adherens junctions leading to the formation of large gaps in the monolayer (Fig 6 C) . Some cell-cell junctions resisted this treatment possibly due to poor accessibility of MβCD to cholesterol rafts. This cell-cell contact destabilization might result from adherens junction disruption possibly caused by VE-cad internalization or degradation. To determine whether VE-cad internalization took place subsequently to MβCD treatment, HUVECs were trypsinized prior to lysis. This trypsinization was used to remove cell surface-expressed VE-cad molecules while leaving intact internalized ones. Western blot analysis revealed that A2
and β-catenin, the loading control, showed no appreciable variation in protein levels (Fig 7 A) .
By contrast, trypsinization degraded the totality of VE-cad in both MβCD-treated and untreated
HUVECs attesting that VE-cad remained at the cell surface following MβCD treatment (Fig 7 A, lanes 2 and 4). This experiment also revealed that following MβCD, VE-cad did not undergo degradation (Fig 7 A, compare lanes 1 and 3) . It could be concluded that destabilization of adherens junctions observed subsequently to MβCD treatment was neither due to the loss of membrane-associated VE-cad nor to its degradation.
To search for the intracellular event involved in such a phenotype, the VE-cad-based complex was isolated by IP from either MβCD-treated or untreated HUVECs and its composition analyzed by Western blotting (Fig 7 B) . Anti-VE-cad IP showed that following MβCD treatment, the VE-cad/catenin complex remained intact. On the contrary, a partial release of A2 from the VE-cad-based complex was observed (Fig 7 B) . Anti-A2 IP confirmed the partial decoupling of A2 from the VE-cad/catenin complex in MβCD-treated cells. Consequently, it could be assumed that the MβCD-induced destabilization of adherens junctions resulted from the release of cholesterol raft associated-A2 and its disconnection from the VE-cad-based complex.
Actin was detected in both anti-VE-cad and anti-A2 IP isolated from confluent endothelial cells (Fig 7 B) . But, after MβCD treatment, actin association was decreased in both VE-cad and A2 immunoprecipitations, therefore A2 exclusion from cholesterol rafts paralleled VE-cad-actin dissociation (Fig 7 B) . Moreover, a drastic reshaping of actin filaments was observed in MβCD-treated cells by immunofluorescence microscopy (Fig 7 C) . Indeed, in control untreated cells, cortical actin fibers were parallel to the cell-cell junctions as defined by and VE-cad labelling. On the contrary, after MβCD treatment, which is known to induce actin fibers re-organization (28), A2 disappeared from most cell-cell contact sites and is so unable to link actin fibers to VE-cad-based complex (Fig 7 C, magnified boxed area) .
Consequently to MβCD treatment, actin fibers adopted a radial orientation and VE-cad exhibited a zig-zag pattern staining at cell-cell junction reminiscent of the immature junction pattern.
Altogether, these results suggest that by connecting the VE-cad-based complex, A2 is a major actor in the maintenance of endothelial adherens junction integrity.
Partners of cholesterol raft-associated annexin 2 potentially involved in the connexion with
VE-cadherin
To determine whether VE-cad and the other proteins constituting the interendothelial adherens junctions were associated with cholesterol rafts, cholesterol-associated proteins were extracted from confluent HUVEC membranes using digitonin, a detergent able to bind exclusively to membrane-linked cholesterol (15). Identification of proteins present within cholesterol rafts was achieved after in-gel digestion by trypsin and analysis of the resulting peptides by mass spectrometry ( Table 1 and complete results available on request to the corresponding author). As expected, clathrin and caveolin-1, two markers of cholesterol rafts, were detected thus attesting that the fractionation was correct. Although this protein extraction method enabled the solubilization of transmembrane proteins such as PECAM-1 and integrin β-1, VE-cad was not detected in the cholesterol rafts ( Table 1) . β-catenin, α-catenin, vinculin and α-actinin were the only proteins belonging to adherens junctions extracted by digitonin treatment (Table 1) . Actin, tubulin and cytoskeleton-associated proteins such as actin-related protein 3
were also detected. In addition to A2, A1, A5 and annexin 6 were also found as well as AHNAK and moesin, two proteins known to belong to cholesterol rafts in other cell types (18, 21).
Western blot analysis mostly confirmed most of the proteomic study i.e. the presence of A2, moesin, α-actinin, β-catenin, PECAM-1 and the absence of VE-cad, γ-catenin and p120 in cholesterol rafts (Fig 8) . Additionally, the phosphatase SHP2 and the A2 partner p11 were also detected using specific antibodies. The only divergence observed between proteomic and
Western blotting analyzes concerned α-catenin that was detected in cholesterol rafts by proteomic study ( Table 1) and not by Western blotting (Fig 8) . Furthermore, the fractionation method illustrated in Fig 8 allowed a quantitative comparison of the amounts of proteins present in each fraction. It could be evaluated by Western blot analysis that approximately 70% of membrane-tethered-A2 and -moesin were concentrated in the cholesterol rafts. As expected, VE-cad, α-and γ-catenins appeared essentially present in the membrane fractions (Fig 8, lanes 2 and 3) whereas p120 distributed between the membrane and the cytoplasm fractions in a 80:20 ratio. IPs of cholesterol raft-associated A2 were performed to assess whether, within rafts, the cholesterol-associated proteins interacted with A2. Among the cholesterol raft-associated proteins, only α-actinin, β-catenin, SHP2, actin and p11 appeared to be connected to cholesterolassociated A2 (Fig 8, lane 5) . Moreover, compared to the raft fraction, the A2
immunoprecipitates were enriched in α-actinin and SHP2 (Fig 8, compare lanes 4 and 5) . These last proteins constitute partners of A2 potentially able to establish the connection between the VE-cad-based complex and the cholesterol rafts.
Effects of VEGF on A2 localization at cell-cell contacts
VEGF is a cytokine known for its capacity to increase vascular permeability. We examined the localization of VE-cad and A2 in HUVECs in the presence or absence of VEGF.
After a 30 min treatment with VEGF, VE-cad staining was greatly disturbed compared to control (Fig 9 A) . At some cell-cell junction sites (Fig 9, VEGF, full arrow heads), VE-cad labelling exhibited a spike pattern reminiscent of what was observed in MβCD-treated cells (Fig 7 C) .
Furthermore, at these particular sites, no A2 was detected at cell-cell contacts. These data suggest that treatment of HUVECs by physiological agonists of vascular permeability such as VEGF may induce the decoupling of the A2/p11 complex from the VE-cad-based junction. To verify this hypothesis, anti-VE-cad IPs were performed on confluent HUVECs treated or not with VEGF (Fig 9 B) . It appeared that, following VEGF treatment, A2 was totally released from the VE-cadbased complex. Concomitantly, the amount of actin co-immunoprecipitated with VE-cad was drastically reduced. Altogether, these data indicated that VEGF treatment results in a VE-cadbased complex/A2 decoupling leading to a partial disconnection of the VE-cad-based complex from the actin cytoskeleton. Firstly, we observed that A2 translocates from the cytoplasm to the plasma membrane and more particularly to cell-cell contact sites as HUVECs become confluent (Fig 1A and 1B) . This correlates with the fact that A2 docks to these specific sites when VE-cad-mediated adherens junctions reach maturity. Although the mechanism underlying the A2 targeting to membrane as cell confluence establishes remains to be elucidated, it probably requires the formation of the heterotetramer (A2) 2 (p11) 2 (12) . Indeed, immunofluorescent labelling of p11 and A2 perfectly overlapped with that of VE-cad at cell-cell junctions (data not shown).
Secondly, using immunoprecipitation experiments, we demonstrated that both A2 and p11 subunits interact with the VE-cad-based complex composed at least of VE-cad, α-, β-, γ-catenins and p120. This interaction is independent of actin filament binding since it is not abolished by drug-induced actin depolymerization treatment (Fig 4) . By contrast, no interaction between A2 and N-cadherin, the other cadherin present in endothelium, was detected. Similarly, A2 does not interact with PECAM1, a receptor expressed at endothelial adherens cell-cell junctions. Moreover, among annexins expressed in the endothelium, only A2 possesses the ability to interact with the VE-cad-based complex.
The fact that the A2/p11 complex interacts with the VE-cad complex when cells reach confluence suggests that it may be involved in the maturation of interendothelial adherens junctions. This hypothesis is supported by the fact that abrogation of the expression of A2 in HUVECs by specific siRNA (Fig 5 A) drastically disturbs the localization of VE-cad at cell-cell junctions (Fig 5 B) . (Fig 6 B) . This results in a destabilization of adherens junctions with formation of intercellular gaps at some cell-cell contact sites (Fig 6 C) . This destabilization is neither due to internalization nor degradation of VE-cad as attested by trypsin digestion experiments (Fig 7A) but from a delocalization of VE-cad from cellcell junctions (Fig 6 C) . siRNA down-regulation of A2 and MβCD-mediated depletion of membrane-associated A2 lead to very similar cellular effects i.e. partial disappearance of VE-cad from cell-cell junctions and a corollary destabilization of adherens junctions. The mechanism by which the disconnection of A2 from the VE-cad complex is induced remains unknown. It can not be excluded that this event may result from the release of signalling proteins usually located in the cholesterol rafts (36). This signalling pathway needs further investigations.
As previously observed, the actin cytoskeleton is absolutely needed to maintain the adherens junction architecture (44). Nevertheless, the connexion between the VE-cad-based complex and actin fibers remains elusive. Our experiments showed that the MβCD-induced disruption of A2 from the VE-cad complex was accompanied by a partial loss of actin in the immunoprecipitation (Fig 7C) . Considering furthermore that A2 is known to strongly interact with actin fibers (23), we assume that the connexion of the VE-cad-based complex might be in part mediated by A2.
In confluent HUVEC, approximately 70% of membrane-associated A2 are localized in cholesterol rafts (Fig 8) . Therefore, connection with the A2/p11 complex indirectly anchors the VE-cad complex to cholesterol rafts. Due to its stoichiometry, the AII/p11 complex may dock several VE-cad-based complexes. Using electron microscopy and biochemical studies, we recently established that each VE-cad complex is formed of hexameric structures in which six molecules of VE-cad associate in an anti-parallel manner (5, 25, 31) . The multiplicity of interactions between the self-associated VE-cad molecules and the A2/p11 complex may lead to the elaboration of a supercomplex embedded in cholesterol rafts. Furthermore, at membrane cholesterol raft sites, the A2/p11 complex mediates in part interactions with the actin cytoskeleton (17, 34, 37). Consequently, once connected to the cholesterol raft-anchored pool of A2, the VE-cad-based complexes may be indirectly bound to actin cytoskeleton. We propose a model of VE-cad-actin interaction through A2. In subconfluent endothelial cells, the VE-cadbased complex freely diffuses laterally in the plasma membrane. Simultaneously with the arrival of A2 at the membrane, the VE-cad-based complex is progressively docked to the A2-containing cholesterol rafts and indirectly linked to the actin cytoskeleton. This entrapment provides a rigid structure that considerably restricts lateral diffusion of the VE-cad-based complex thus strengthening and stabilizing adherens junctions in confluent endothelial cells (Fig 10) . This correlates with observations made in myoblasts in which N-cadherin lateral diffusion is increased when raft structures are disrupted (9).
To determine how the VE-cad-based complex and A2 are inter-connected, the cholesterol raft-associated proteins were isolated by digitonin extraction of cholesterol-bound proteins combined with ultracentrifugation. Identification of these proteins was obtained after their in-gel digestion by trypsin and analysis of the resulting peptides by mass spectrometry ( Table 1 and Fig 8) . Strikingly, VE-cad was not detected within the cholesterol raft-associated protein fraction whereas A2 was found. This suggests that the connection between the VE-cad-based complex and A2 is mediated through intermediate proteins possibly identified as those associated with A2 within cholesterol rafts. Our proteomic analysis reveals that, in cholesterol rafts, A2 interacts with actin, β-catenin, α-actinin, p11 and SHP2 (Fig 8, lane 5) . This suggests that these last three proteins constitute candidates able to potentially connect A2 to the VE-cad/β-catenin complex.
Among the identified proteins, the phosphatase SHP2 is an interesting candidate. Indeed, on one hand, it was demonstrated to co-immunoprecipitate with the VE-cad-based complex by selectively interacting with β-catenin in confluent quiescent HUVECs (40). This interaction maintains β-catenin under its dephosphorylated form (6, 27). On the other hand, immunoprecipitation experiments performed on confluent cow pulmonary aortic endothelial cells revealed that SHP2 co-immunoprecipitates with A2 (7). Moreover, tyrosine phosphorylation of SHP2 promotes its dissociation from the VE-cad-based complex when HUVECs were activated by agonists able to increase vascular permeability such as thrombin (40). This correlates with a drastic increase in tyrosine-phosphorylation of β-catenin. Consequently, the ability to associate with the VE-cad-based complex in a tyrosine phosphorylation-dependant manner may confer the capacity to regulate the interaction between A2 and the VE-cad-based complex to the cholesterol raft-tethered pool of SHP2.
During the angiogenesis process, endothelial cell-cell junctions become leaky and endothelial cells acquire the capacity to migrate, two events leading to the constitution of new vessels (41, 43). The increase of vascular permeability might be correlated with the disconnection of A2 from the VE-cad-based complex. To test this hypothesis, we submitted confluent HUVEC monolayers to VEGF, a cytokine able to induce in vivo and in vitro angiogenesis processes (14, 29). Following this treatment, the junctional localization of A2 was dramatically disturbed (Fig 9 A) . In fact, we showed that A2 and actin are decoupled from the VE-cad-based complex subsequently to VEGF treatment (Fig 9 B) . This suggests that the VEGFinduced increase in vascular permeability might be a consequence of the disconnection of the actin cytoskeleton from the VE-cad-based complex. MβCD induces the phosphorylation of p120 and γ-catenin (10). In both cases, phosphorylation of the adherens junction components is induced by loss of SHP2 or destabilisation of cholesterol rafts, two phenomena that implicate the plasma membrane-associated pool of A2. Whether the VE-cad/A2 disconnection is linked to the phosphorylation status of VE-cad-based complex remains to be explored.
In the present manuscript, we provide evidence for the existence of a novel mechanism able to promote the maturation of the interendothelial adherens junctions. By connecting the VEcad-based complex to the cholesterol raft-tethered pool of A2, a stabilization of adherens interendothelial junctions occurs allowing the switch from an immature to a mature state. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50 36. respectively. For comparison, aliquots of whole cell lysates (Lys) were analyzed in parallel.
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Molecular weight markers (kDa) are given at the left margin of each blot. Tris-Glycine gels and probed for VE-cad, α-, β-, γ-catenins (α-, β-, γ-cat), actin and A2.
Molecular weight markers (kDa) are given at the left margin of the blot. immunoprecipitations were performed on the digitonin-extracted cholesterol raft fraction (lane5).
After separation on 4-12% gradient precast Criterion XT gels, immunoprecipitates were probed for A2, VE-cad, α-, γ-, β-catenins (α-, β-, γ-cat), p120, moesin, α-actinin, actin, SHP2, and PECAM-1. Immunoprecipitations were also resolved on 15% Tris-Tricine gels and probed for p11. Proteins unambiguously identified were labelled with arrows. Molecular weight markers (kDa) are given at the left margin of the blots. In subconfluent HUVECs, adherens junctions are immature and poorly associated with the actin cytoskeleton. The VE-cad-based complex is free to move laterally in the plasma membrane.
Once HUVECs reach confluence and adherens junctions become mature, the A2/p11 complex, which accumulates underneath the plasma membrane at cholesterol raft sites (CR), associates with the VE-cad-based complex. Consequently, the complex is docked to cholesterol rafts. Thus, by providing a link between the VE-cad/catenin complex and the actin cytoskeleton, the cholesterol raft-embedded A2 stabilizes the adherens junctions, thereby allowing the development of stable intercellular connections.
Supplementary data Fig S1: Co-localization of A2 and VE-cad in confluent HUVECS
Cells were plated on glass coverslips, cultured for three days, and then stained with mAb anti-A2, pAb anti-Cad3, Alexa 488-labelled goat-anti-mouse and Cy5-labelled goat-anti-rabbit antibodies. Nuclei were conterstained with DAPI (blue). Images correspond to a ≈650nm confocal optical section. Bar: 20 µm. 
